Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
CA |
|
C
|
China Oceanwide Holdings Ltd
HKEX:715
|
HK |
|
Ourgame International Holdings Ltd
HKEX:6899
|
CN |
|
IVF Hartmann Holding AG
LSE:0QQM
|
CH |
|
Tilray Brands Inc
NASDAQ:TLRY
|
US |
|
Danone SA
PAR:BN
|
FR |
|
nCino OpCo, Inc.
NASDAQ:NCNO
|
US |
|
Emami Ltd
NSE:EMAMILTD
|
IN |
|
PNB Housing Finance Ltd
NSE:PNBHOUSING
|
IN |
|
Hangzhou Huning Elevator Parts Co Ltd
SZSE:300669
|
CN |
|
Hebei Sinopack Electronic Technology Co Ltd
SZSE:003031
|
CN |
|
S
|
Sonmez Pamuklu Sanayii AS
IST:SNPAM.E
|
TR |
|
Nexj Systems Inc
TSX:NXJ
|
CA |
|
AIMA Technology Group Co Ltd
SSE:603529
|
CN |
|
Muyuan Foods Co Ltd
SZSE:002714
|
CN |
|
Everbright Grand China Assets Ltd
HKEX:3699
|
HK |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
US |
|
I
|
I Sens Inc
KOSDAQ:099190
|
KR |
Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
